Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetrexate and Leucovorin in Recurrent Childhood ALL, NHL, and Osteosarcoma
NCT00002738Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 1996
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trimetrexate glucuronate in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and osteosarcoma (OS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Efficacy of trimetrexate glucuronate with leucovorin calcium rescue at 16 weeks and Toxicity of the treatment regimen at 16 weeks. Started Jan 1996; status: completed.
02
Drugs
trimetrexate glucuronate
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00002738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002738.